BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [PMID: 35317174 DOI: 10.4254/wjh.v14.i2.319]
URL: https://www.wjgnet.com/1007-9327/full/v14/i2/319.htm
Number Citing Articles
1
Alireza Beheshti Maal, Mohammad Amin Shahrbaf, Bahareh Sadri, Nikoo Hossein-Khannazer, Mohammad Ali Mansournia, Massoud Vosough. Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1.7 Million PatientsJournal of Crohn's and Colitis 2024; 18(3): 360 doi: 10.1093/ecco-jcc/jjad157
2
Paul‐Henry Koop, Constanze Schwenzer, Jan Clusmann, Mara S. Vell, Julius Jaeger, Wenfang Gui, Christian Trautwein, Alexander Koch, Tony Bruns, Carolin V. Schneider, Kai Markus Schneider. Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐StudyLiver International 2024;  doi: 10.1111/liv.15945
3
Pilar Navarro, Lucía Gutiérrez-Ramírez, Antonio Tejera-Muñoz, Ángel Arias, Alfredo J. Lucendo. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel DiseaseNutrients 2023; 15(21): 4507 doi: 10.3390/nu15214507
4
Javier Pérez-Valenzuela, Lorena Castro Solari, Rodrigo Quera, Luis Contreras . Mesalamine induced hepatotoxicity. Is mesalamine safe?Revista Española de Enfermedades Digestivas 2024;  doi: 10.17235/reed.2024.10131/2023